Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations. Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT05768178
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:56.587096+00:00
Published At
2025-11-24T00:00:00+00:00
Record Updated At
2025-11-24
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Haematological Malignancy", "Melanoma", "Thyroid Cancer, Papillary", "Ovarian Neoplasms", "Colorectal Neoplasms", "Laryngeal Neoplasms", "Carcinoma, Non-Small-Cell Lung", "Glioma", "Multiple Myeloma", "Erdheim-Chester Disease", "Thyroid Carcinoma, Anaplastic", "Solid Tumour"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-11-24"
protocolSection.identificationModule.nctId
"NCT05768178"
protocolSection.identificationModule.officialTitle
"DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations. Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers."
protocolSection.statusModule.overallStatus
"RECRUITING"
protocolSection.designModule.phases
["PHASE2", "PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Haematological Malignancy (protocolSection.conditionsModule.conditions)
  • Melanoma (protocolSection.conditionsModule.conditions)
  • Thyroid Cancer, Papillary (protocolSection.conditionsModule.conditions)
  • Ovarian Neoplasms (protocolSection.conditionsModule.conditions)
  • Colorectal Neoplasms (protocolSection.conditionsModule.conditions)
  • Laryngeal Neoplasms (protocolSection.conditionsModule.conditions)
  • Carcinoma, Non-Small-Cell Lung (protocolSection.conditionsModule.conditions)
  • Glioma (protocolSection.conditionsModule.conditions)
  • Multiple Myeloma (protocolSection.conditionsModule.conditions)
  • Erdheim-Chester Disease (protocolSection.conditionsModule.conditions)
  • Thyroid Carcinoma, Anaplastic (protocolSection.conditionsModule.conditions)
  • Solid Tumour (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.